• The Online Submission Platform for ERDERA’s Joint Transnational Call 2025 is Now Live

    January 21st, 2025

    We are pleased to announce that the platform for submitting project applications for the Joint Transnational Call for Proposals (JTC) 2025 is now officially live. This highly anticipated call invites research teams across Europe and internationally to collaborate on cutting-edge projects aimed at “Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation.” 

  • A New Era in Rare Disease Diagnosis: How Big Data and Pan-European Collaboration are Changing Lives

    January 20th, 2025

    For decades, rare disease patients and their families have endured a painful “diagnostic odyssey,” bouncing between specialists and often going years without answers. Rare diseases, by definition, affect fewer than 5 in 10,000 people in the European Union, but with over 7,000 such conditions cataloged, their collective impact is profound. A staggering 70% of these diseases are genetic, yet pinpointing the precise DNA mutation responsible has often been a Herculean task. Now, thanks to an unprecedented pan-European collaboration and advances in big data analysis, hope is on the horizon for those with previously unsolved rare diseases. 

  • Slovenia Joins ERDERA’s Joint Transnational Call for Proposals on Rare Disease Therapies

    January 16th, 2025

    We are delighted to announce that the Ministry of Health of the Republic of Slovenia (Ministrstvo za zdravje) has officially joined the funding organisations participating in the first Joint Transnational Call for Proposals on Rare Disease Therapies. This initiative is part of ERDERA’s ongoing commitment to advancing cutting-edge research in this critical area.

  • Join ERDERA’s Extended Webinar on the Joint Transnational Call on 14 January

    January 8th, 2025

    Following the success of our previous session, ERDERA warmly invites researchers, patient advocates, and early-career professionals to an extended webinar on 14 January 2025. This webinar is part of the 2025 Joint Transnational Call for Proposals, “Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation”, which was officially launched on 10 December 2024.

  • ERDERA Launches the 2025 Joint Transnational Call for Proposals on Rare Disease Therapies 

    December 10th, 2024

    The European Rare Diseases Research Alliance (ERDERA) is delighted to announce the official launch of its 2025 Joint Transnational Call (JTC) for Proposals as of today, 10 December 2024. This eagerly anticipated call invites research teams across Europe and internationally to collaborate on cutting-edge projects aimed at “Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation.” 

  • Join the 2025 Joint Transnational Call Webinar on 17 December

    November 29th, 2024

    The European Rare Diseases Research Alliance (ERDERA) is delighted to invite researchers, patient advocates, and early career professionals to a key webinar on 17 December 2024, following the official launch of the 2025 Joint Transnational Call for Proposals for “Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation” on 10 December.

  • Looking Forward to the 8th RE(ACT) Congress and IRDiRC Conference 2025

    November 25th, 2024

    From 5–7 March 2025, the global rare disease community will convene for a landmark event: the 8th RE(ACT) Congress & IRDiRC Conference. Taking place in Brussels, this gathering is jointly organised by the BLACKSWAN Foundation and the International Rare Diseases Research Consortium (IRDiRC).  

  • ERDERA’s Coordinator, Daria Julkowska, Participates in Rare Disease Moonshot Debate Hosted by Euronews

    November 14th, 2024

    The Innovating for Impact: Shaping the Future of Rare Disease Treatment event, hosted by Euronews and organised by Rare Disease Moonshot, brought together key figures in rare disease advocacy to discuss the future of treatment in Europe.